Quinoline derivatives for modulating DNA methylation

US7939546B2 · kind B2 · utility

Assignee

• Supergen, Inc. · US

Inventors

• Pasit Phiasivongsa · Brentwood, US
• Sanjeev Redkar · San Ramon, US
• Swarna Gamage · Auckland, NZ
• Darby Brooke · Auckland, NZ
• William Alexander Denny · Beachlands, NZ
• David J. Bearss · Alpine, US
• Hariprasad Vankayalapati · Draper, US
• Yong Xu · Midvale, US
• Krzysztof Swierczek · West Jordan, US

Key dates

• Filing date: Apr 10, 2009
• Grant date: May 10, 2011
• Expiry date: Apr 10, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Quinoline derivatives, particularly 4-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine-2-carboxylic acid; 3-(4-(4-(quinolin-4-ylamino)benzamido)phenylthio)pyrrolidine; N-(4-(piperidin-4-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide; and N-(4-(piperidin-3-ylthio)phenyl)-4-(quinolin-4-ylamino)-benzamide, or a physiologically acceptable salt thereof, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.